Sulfasalazine
Brand names: Azulfidine, Sulfasalazine, Sulfasalazine Dr
At a glance
- Medicare prescriptions, 2024
- 404,363
- Medicare drug cost
- $12.2M
- Average cost per prescription
- $30.06
- Clinicians who prescribed it
- 9,730
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
SULFASALAZINE DELAYED RELEASE Tablets, USP are indicated: a)in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis;b)for the prolongation of the remission period between acute attacks of ulcerative colitis;c)in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); andd)in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs.
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Rheumatology 59.1%
- Nurse Practitioners 11.8%
- Physician Assistants 8.2%
- Internal Medicine 7.1%
- Gastroenterology 6.4%
- Family Medicine 4.9%
- Geriatric Medicine 0.7%
- General Practice 0.5%
- Allergy & Immunology 0.2%
- Hospitalist 0.1%
- Colorectal Surgery 0.1%
- General Surgery 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 0% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +30%
- Arkansas +21%
- Louisiana +20%
- Oklahoma +20%
- Missouri +9%
- Oregon (smallest change) −15%
- Massachusetts (smallest change) −15%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Mylan Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | yellow oval tablet, 18 mm | 104 |
Pfizer Laboratories Div Pfizer Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | yellow oval tablet, 18 mm | 102 KPH |
Sunrise Pharmaceutical, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | yellow oval tablet, 18 mm | N40 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.